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ABSTRACT 
A simple, rapid, precise, rapid, sensitive and reproducible reverse phase high performance liquid 
chromatographic (RP-HPLC) method for determination of Telmisartan in tablet dosage form was 
developed and validated. Chromatographic separation was achieved on a 250 × 4.6 mm, 5µ, Waters 
symmetry column in gradient mode, with mobile phase consisting of a mixture of solution (10 mM 
potassium dihydrogen phosphate, pH 3.5 ± 0.01): acetonitrile (64:40) was used. The quantitation 
performed at flow rate of 1.0 ml/min at 230 nm and run time was 12 min. The analytical method was 
validated as per ICH guideline for linearity, accuracy, precision, specificity, limit of detection, limit of 
quantification, robustness and stability and method can be extended to the analysis of Telmisartan in 
tablet formulations. The relative standard deviation values for precision was less than 2%, and % 
recovery was greater than 98% for Telmisartan. The drug undergoes oxidative degradation, thermal 
degradation and in alkali medium. 
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1.  Introduction: 
Telmisartan (TELM) chemically described as 
4[(1,4‐dimethyl‐  2‐  propyl (2,6‐bi ‐1H‐ 
benzimidazol]‐1‐yl) methyl] 
[1,1‐biphenyl]‐2‐carboxylic acid is a potent, 
long‐lasting, nonpeptide antagonist of the 
angiotensin II (AT1) receptor that is indicated 
for the treatment of essential hypertension. It 
selectively and insurmountably inhibits 
stimulation of the AT1 receptor by angiotensin 
II without affecting other receptor systems 
involved in cardiovascular regulation. In clinical 
studies, TELM shows comparable 
antihypertensive activity to other major 
antihypertensive classes, such as angiotensin 
converting enzyme (ACE) inhibitors, 
beta‐blockers and calcium antagonists (1, 2). 
A novel formulation commercially available in 
Telmisartan, benefits from the complementary 
modes of action of long‐lasting angiotensin 
receptor. This provides powerful efficacy for 
day long control of BP and has proven evidence 
in cardiovascular (CV) outcomes of Telmisartan. 
Literature review revealed that there are various 
methods for determination of Telmisartan, 
individually and in combination with other 
drugs. A variety of analytical methods for 
estimation of Telmisartan are previously 
reported. The majority of methods reported are 
liquid chromatography coupled to UV, tendem 
mass spectrometry or mass spectrometry 
detection but some determinations were also 
performed by thin layer, ratio derivative 
spectrophotometry and spectrofluorimetry. 
Individually, Telmisartan is estimated by LC-
MS (3), LC-tendem MS (4, 5). The majority of 
methods reported are liquid chromatography in 
which Telmisartan was estimated 
simultaneously with hydrochlorothiazide (6, 7, 8), 
with ramipril (9, 10), with Amlodipine (11). Some 
triple combinations are also reported along with 
telmisartan such as, Column Switching LC with 
fluorescence detection (12). Some HPTLC 
methods are also reported for estimation of 
Telmisartan along with other drugs (13, 14, 15). 
None of these analytical procedures has been 
described as a stability-indicating method for 
analysis of TELM in the presence of its 
degradation products. 
Stress testing carried out to elucidate the 
inherent stability characteristic of the active 
substances and forms an important part of the 
API and drug product development. It suggests 
that degradation products that are formed under 
a variety of conditions should be identified and 
degradation pathways be established. The 
purpose of stress testing is to provide evidence 
on how the quality of drug substance varies with 
time under the effect of varieties of 
environmental factors such as acidic/alkaline 
medium, temperature, humidity, light and 




presence of oxygen. An ideal stability-indicating 
method is one that quantifies the drug and also 
resolves its degradation products (14). 
The aim of present work is to develop a simple, 
specific, sensitive, accurate and stability 
indicating HPLC analytical procedure for the 
analysis of Telmisartan in tablet dosage form in 
the presence of its degradation products and 
related impurities as per ICH guideline (15). 
 
2. Experimental: 
a. Chemicals: Telmisartan (99.4%) was 
obtained from Cipla Pharmaceutical Ltd, 
Mumbai, India, as gift samples. Acetonitrile 
(HPLC Grade), Methanol (HPLC Grade), 
Potassium di hydrogen phosphate (AR Grade), 
ortho‐phosphoric acid (AR Grade) were 
purchased from E. Merck (India) Ltd. The 
0.45‐µm nylon filters were purchased from 
Advanced Micro Devices Pvt. Ltd. Chandigarh, 
India. Mili‐Q water was used throughout the 
experiment. Tablets were purchased from Indian 
market containing of Telmisartan 40mg per 
tablet. 
b. Instruments: Analysis was performed on a 
chromatographic system Agilent 1200 series 
separation module (Japan) equipped with an 
auto injector (G1329A), Diode array detector SL 
(G1315C), Quaternary pump (G1311A) and 
column thermostat (G1316A). Data acquisition 
was made with Chemstation software. The peak 
purity was evaluated with DAD detector. 
c. Liquid chromatographic conditions: 
Chromatographic conditions were obtained 
using a stainless steel column (Waters symmetry 
C18 250mm x 4.6mm 5µm), which was 
maintained at 40 ⁰C. The analytical wavelength 
was set at 230 nm and samples of 20µl were 
injected to HPLC system. The mobile phase was 
Potassium dihydrogen phosphate (10mM, pH 
3.0 adjusted with ortho‐phosphoric acid) and 
acetonitrile in ratio of 60:40 (v/v) (isocratic) at a 
flow rate of 1ml/min. For degradation study the 
mobile phase was Potassium dihydrogen 
phosphate (10mM, pH 3.0 adjusted with 
ortho‐phosphoric acid) and acetonitrile in ratio 
of 60:40 (v/v) to 70:30 (v/v) (gredient) at a flow 
rate of 1ml/min. The mobile phase was filtered 
through 0.45µm filter and degassed for 10 
minutes by sonication.  
d. Standard solutions:  
1. Stock standard solutions:  An accurately 
weighed quantity of 40 mg of Telmisartan was 
transferred into a 100 ml volumetric flask. 
Dissolved with 30 ml of methanol and diluted to 
required volume with mobile phase, having the 
concentration of 400 µg/ml of Telmisartan.  
2. Preparation of working standard: From the 
standard stock solution 10 ml is pipette out into 
100 ml volumetric flask and made up the 
volume with mobile phase, having the 
concentration of 40 µg/ml of Telmisartan. 
3. Preparation of laboratory mixture: 
Accurately weighed quantities of TELM (≈ 40 
mg) was transferred into a 100 ml volumetric 
flask, than dissolved with 30 ml of methanol and 
diluted to required volume with mobile phase, 
having the concentration of 400 µg/ml of 
TELM. An accurately measured 1.0 ml portion 
of the resultant solution was diluted to 10.0 ml 
with diluent to obtain a laboratory mixture 
having concentration similar to marketed 
formulation. 
4. Sample preparation:  Twenty tablets 
(CRESAR, Cipla Pharmaceutical Ltd.) were 
weighed and ground to a fine powder. An 
amount of powder equivalent to 40mg of 
Telmisartan was weighed accurately and 
transferred into a 100 ml A‐grade volumetric 
flask containing 30 ml of methanol and 
sonicated for 30 min to effect complete 
dissolution of the Telmisartan and diluted upto 
100 ml with diluent, then the solution was 
filtered through 0.45 µm membrane filter and 10 
ml of filtrate taken into 100 ml volumetric flask. 
The aliquot portion of the filtrate was further 
diluted to get final concentration of 40 µg/ml of 
Telmisartan.  
e. Linearity study and Calibration curve: To 
study the linearity range of component, serial 
dilutions were made to obtain working standards 
in the concentration range of Telmisartan (10‐50 
µg/ml). A graph was plotted as concentration of 
drugs versus peak area response and results 
found linear for analytes. From the standard 
stock solution, a mixed standard of working 
concentration was prepared containing 
Telmisartan (40 µg/ml). The system suitability 
test was performed from five replicate injection 
of mixed standard solution. 
f. Procedure for Forced Degradation Study: 
Stability testing is an important part of the 
process of drug product development. The 
purpose of stability testing is to provide 
evidence of how the quality of a drug substance 
or drug product varies with time under a variety 
of environmental conditions, for example 
temperature, humidity, and light, and enables 
recommendation of storage conditions, retest 
periods, and shelf life to be established. The two 




main aspects of drug product that play an 
important role in shelf-life determination are 
assay of the active drug and the degradation 
products generated during stability studies. The 
objective of this work was to develop an 
analytical LC procedure which would serve as a 
stability-indicating method for assay of TELM 
drug product. Forced degradation of the drug 
product was carried out under thermolytic, 
photolytic, acid/base hydrolytic, and oxidative 
stress conditions. Forced degradation of the drug 
products under acidic, basic, and oxidizing 
conditions was performed using centrifuged and 
filtered solution (as described in the section 
‘‘Preparation of Sample Solution’’) containing 
10 µg/ml TELM. For thermolytic and photolytic 
degradation, a quantity of powder equivalent to 
10 mg TELM was exposed.  
Acidic Degradation: Centrifuged sample stock 
solution (1 ml) was transferred to a 10 ml 
volumetric flask and 3 ml 1 M HCl was added. 
The mixture was left at 60 0C for 8 h in a water 
bath then left to equilibrate to ambient 
temperature, then diluted to 10 ml with diluent. 
Alkaline Degradation: Centrifuged sample 
stock solution (1 ml) was transferred to a 10 ml 
volumetric flask and 3 ml 0.01 M NaOH was 
added. The mixture was left for 10 min at 
ambient temperature, then diluted to 10 ml with 
diluent. 
Oxidative Degradation: Centrifuged sample 
stock solution (1 ml) was transferred to a 10 ml 
volumetric flask and 3 ml 30% H2O2 was added. 
The mixture was left for 2 h at ambient 
temperature then diluted to 10 ml with diluent. 
Thermal Degradation: Approximately 250 mg 
drug product powder was left at 300C, 400C, 
500C for 1 month. The sample was then treated 
to obtain solution containing 10 µg/ml TELM. 
UV Degradation: Approximately 250 mg drug 
product powder was exposed to short-
wavelength UV light for 24 h. The sample was 
then treated to obtain solution containing 10 
µg/ml  TELM. 
g. Analysis of Laboratory Mixture: In order to 
establish suitability of the proposed method for 
quantative estimation of Telmisartan in the 
pharmaceutical formulations, the method was 
first tried for the estimation of the component in 
a standard laboratory mixture of two drugs by 
using eq. 1and 2.  
h. Analysis of Marketed Formulation: 20 µl of 
the standard and sample are injected separately 
and chromatograms are generated. With peak 
area obtained for standard and sample, the 
content of TELM in each tablet was calculated 
using the following equation: 
Amount of drug present in each tablet =   
Sample area x Std. Conc. x Std. Purity x Avg. weight 
                       Std. area x Sample conc.   
                    ………………. (1)   
                                         Amount present 
Percentage label claim =      Label claim    x 100    …… (2) 
                                             
                                                 
i. Recovery study: Recovery studies were 
performed to validate the accuracy of developed 
method. For recovery study different 
concentrations (50%, 100% and 150%) of 
standard drug was prepared and then its recovery 
was analyzed. 
j. Method validation: The HPLC method was 
validated in terms of precision, accuracy, 
specificity and linearity according to ICH 
guidelines (22).  
Accuracy: The accuracy of the assay method 
was evaluated with the recovery of the standards 
from excipients. Three different quantities (low, 
medium and high i.e. 50%, 100% and 150%) of 
the authentic standards were added to the 
placebo. The mixtures were extracted as 
described in section 2d, and were analyzed using 
the developed HPLC method. 
Precision: Assay method precision was 
determined using nine‐independent test solutions 
(3 concentration/3 replicates). To study 
precision 80%, 100% and 120% concentration 
was prepared and three replicate of each 
concentration was injected. The intermediate 
precision of the assay method was also evaluated 
using different analyst different days. 
Specificity: Accurately weighed quantities of 
the tablets powder equivalent to about 40 mg of 
TELM was taken in a dry 50.0 ml volumetric 
flask. Each sample solution was stored under 
following different relevant small stress 
conditions (light, heat, acid/base hydrolysis and 
oxidation) for sufficient time (24 hrs) to achieve 
10 to 30% degradation of the initial sample. 
1. Addition of small amount of alkali solution 
(0.1 N NaOH).  
2. Addition of small amount of acid solution 
(0.1 N HCl). 
3. Addition of small amount of oxidative agent 
(3% H2O2). 
4. Sample solution was heated 50 0C on water 
bath for a sufficient time 
5. Sample solution was exposed 600 foot-
candle of UV light for a sufficient time. 
 




After 24 hr each treated sample was analyzed 
and percent labeled claims were calculated by 
the method using formula under estimation of 
TELM by proposed method. 
 
Linearity: Solutions for linearity study were 
prepared as described in Section 2e. Six 
replicates of each concentration were injected 
and results are examined and it was found that 
calibration curve was linear in the concentration 
range of 10-50 µg/ml for TELM with correlation 
coefficient (R2) 0.999.  
LOD and LOQ: The LOD and LOQ for 
analytes were estimated by SD of injecting a 
series of dilute solutions of known 
concentrations.  
Ruggedness: Ruggedness was ascertained by 
getting the sample analyzed from different 
analysts and carrying out analysis on different 
days by proposed method. 
Robustness: To determine the robustness of the 
method, the final experimental conditions were 
altered and the results were examined. The ratio 
of mobile phase was varied. 
 
3. Results and Discussion: 
3.1 Optimization of the chromatographic 
conditions: In order to develop RP‐HPLC 
method for cardiovascular drugs Telmisartan in 
formulation. The chromatographic conditions 
were optimized for better resolution by using 
different buffers like phosphate, acetate and 
citrate for mobile phase preparation. After a 
series of screening experiments, it was 
concluded that Phosphate buffer (10mM 
Phosphate buffer pH at 3.0) gave better peak 
shapes than their acetate and citrate counterparts. 
With methanol as solvent both the peaks shows 
less theoretical plates and bad peak shapes, on 
changing to acetonitrile the peak shape 
improved along with theoretical plates. Further 
optimization experiments were carried out 30% 
and 40% of acetonitrile in mobile phase. The 
best peak shape and maximum separation was 
achieved with mobile phase composition 
consisting acetate buffer‐acetonitrile (60:40 v/v). 
The best separation, peak symmetry and 
reproducibility were obtained on Waters 
symmetry C18, 250 mm x 4.6 mm, 5 µm column 
compared to Hypersil ODS, C18, 250 mm x 4.6 
mm, 5 µm. The optimum wavelength for 
detecting the analytes was ascertained and found 
to be 230 nm.  
Method development studies of TELM from its 
degradation products revealed that pot. Di 
hydrogen phosphate: Acetonitrile (60:40)  was 
used which vary to (70:30 v/v) (gradient 
method) at a flow rate of 1.0 ml/min and a 
column temperature of 400C were suitable 
conditions for a stability-indicating method for 
study of the degradation of TELM. TELM peak 
shape was good, with little tailing, and TELM 
was well resolved from its degradation products. 
The retention time of TELM was, typically, 
approximately 28.82 min and chromatographic 
analysis time was than 70 min. Under the 
optimized conditions TELM and its degradation 
products were well separated. 
Although the conditions used for forced 
degradation were attenuated to achieve 
degradation in the range 10–30%, this could not 
be achieved for thermal and photolytic 
degradation even after prolonged exposure. 
During the initial forced degradation 
experiments it was observed that alkaline 
hydrolysis of TELM was a rapid reaction the 
drug was extensively degraded by alkali 
hydrolysis, thermal and oxidative condition. 
Table 1 indicates the extent of degradation, and 
assay of TELM under the various stress 
conditions.  Chromatograms obtained from 
TELM tablet solution, and solutions after 
thermal degradation and alkaline hydrolysis of 
the drug product are shown in Table 6. 
Accuracy of the method was calculated by 
recovery studies at three levels by standard 
addition method (Table 1). The mean percentage 
recoveries obtained for Telmisartan were 
100.196. 
Precision is the degree of repeatability of an 
analytical method under normal operational 
conditions. The system precision is a measure of 
the method variability that can be expected for a 
given analyst performing the analysis and was 
determined by performing 80%, 100% and 
120% analyses of the working solution.  
The intra‐day, inter‐day, analyst and instruments 
variability or precision data are summarized in 
Table 3.The R.S.D of the assay results, 
expressed as percentage of the label claim, was 
used to evaluate the method precision. The 
inter‐day precision was also determined by 
assaying the tablets in triplicate per day. The 
results indicated the good precision of the 
developed method. 
The developed method was applied to the 
analysis of Telmisartan in tablet dosage from 
marketed as Cresar (Label claim 40 mg strength, 
Cipla Pharmaceutical Ltd.). The contents of 
marketed tablet dosage form were found to be in 




the range of 100±2% with RSD less than 2% 
which indicate suitability for routine analysis of 
Telmisartan in tablet dosage form. 
The robustness of an analytical procedure is a 
measure of its capacity to remain unaffected by 
small, but deliberate variations in method 
parameters and provides an indication of its 
reliability during normal usage. Robustness of 
the method was investigated under a variety of 
conditions including changes of pH of the 
mobile phase, flow rate, percentage of 
acetonitrile in the mobile phase. The mixed 
standard solution is injected in five replicates 
and sample solution of 100% concentration is 
prepared and injected in triplicate for every 
condition and % R.S.D. of assay was calculated 
for each condition. The degree of reproducibility 
of the results obtained as a result of small 
deliberate variations in the method parameters 
has proven that the method is robust (Table 4). 
 
Conclusion: 
In this study, a selective and validated stability-
indicating RP-HPLC assay method for 
Telmisartan was developed, which could 
separate the drug and its degradation products 
formed under a variety of stress conditions. 
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50 49.95 99.9 0.011 
100 99.942 99.94 0.005 
150 151.122 100.748 0.003 
 
Table 2 System suitability Parameter of Telmisartan 
 
Parameters Atorvastatin 
Theoretical plates 8721 
Peak Height 7.56 
Peak Symmetry 0.981 
USP tailing 1.018 
Width at half height 0.389 
 
Table 3 Results of precision of Telmisartan 
 
Compound Precision Mean RSD (%) 
Telmisartan 
Intra day 100.55 0.007 




Table 4 Results of robustness study of Telmisartan 
 
Factor Level Mean % 
assay (n=3) 
RSD (%) 
pH of mobile phase 3 99.5 0.209 
3.2 99.0 0.210 
Flow rate (ml/min) 1 99.6 0.057 
1.3 99.3 0.209 
% of Acetonitrile 30 99.1 0.307 
40 100.8 0.198 
 
Table 5 Quantitative analysis of marketed formulation of Telmisartan 
 







TELM 40 39.66 99.15 -0.85 
 




Table 6 Results of forced degradation study 
 
Stress condition Degradation % of TELM % Assay 
Thermal Stress 30 0C 3.16 96.84 
 40 0C 7.88 92.12 
 50 0C 18.64 81.36 
Alkaline stress 0.1 N NaOH, 8h 8.8 91.20 
 1 N NaOH, 12h 27.84 72.16 
 2 N NaOH, 24h 38.29 61.71 
Oxidative stress 3 %, 6 h No Degradation 99.28 
 3 %, 24 h No Degradation 99.18 
 10 %, 24 h 3.18 96.88 
Acidic stress 0.1 N HCl / 8 h No Degradation 99.28 
 1 N HCl / 12 h No Degradation 99.25 
 2 N HCl / 24 h No Degradation 99.25 
 5 N HCl / 24 h No Degradation 99.19 
UV stress 1.2×106 Lux hours No Degradation 99.18 
 6×106 Lux hours No Degradation 99.19 
 
 
 
